RTW INVESTMENTS, LP
RTW INVESTMENTS, LP's purchase track record
How the stock did after each of RTW INVESTMENTS, LP's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/20/2026 | KLRA | $8.00M | -27.2% | pending | — |
| 4/29/2025 | OBIO | $276K | +24.9% | +49.8% | +23.9% |
| 10/6/2022 | RCKT | $20.00M | +8.2% | -6.2% | +9.6% |
| 9/7/2022 | MIST | $13.56M | -47.1% | -57.1% | +0.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Kailera Therapeutics faces scrutiny on weight loss differentiation. Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial. Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.
Transaction History
| OBIO | ▼ Sell | Other | 1,250,032 | $125 | 4/27/2026 | View on chart |
| OBIO | ▼ Sell | Open Market | 32 | $132 | 4/27/2026 | View on chart |
| KLRA | ▼ Sell | Other | 10,276,820 | — | 4/20/2026 | View on chart |
| KLRA | ▲ Buy | Open Market | 500,000 | $8.0M | 4/20/2026 | View on chart |
| RCKT | ▼ Sell | Other | 59,000 | $183K | 9/19/2025 | View on chart |
| RCKT | ▼ Sell | Other | 41,000 | $127K | 9/19/2025 | View on chart |
| RCKT | ▼ Sell | Other | 59,000 | $1.1M | 9/19/2025 | View on chart |
| RCKT | ▼ Sell | Other | 1,000,000 | $40.0M | 9/19/2025 | View on chart |
| RCKT | ▼ Sell | Other | 1,000,000 | $3.1M | 9/19/2025 | View on chart |
| RCKT | ▼ Sell | Other | 41,000 | $783K | 9/19/2025 | View on chart |
| OBIO | ▲ Buy | Open Market | 49,900 | $149K | 4/30/2025 | View on chart |
| OBIO | ▲ Buy | Open Market | 50,000 | $126K | 4/29/2025 | View on chart |
| RCKT | ▼ Sell | Other | 500,000 | $11.0M | 8/28/2023 | View on chart |
| RCKT | ▼ Sell | Other | 500,000 | $7.9M | 8/28/2023 | View on chart |
| RCKT | ▼ Sell | Other | 500,000 | $7.9M | 8/28/2023 | View on chart |
| RCKT | ▼ Sell | Other | 500,000 | $11.0M | 8/28/2023 | View on chart |
| OBIO | ▼ Sell | Other | 502,133 | — | 4/13/2023 | View on chart |
| MIST | ▼ Sell | Other | 1,059,000 | — | 3/22/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 2,310,000 | — | 1/26/2023 | View on chart |
| RCKT | ▼ Sell | Other | 529,038 | — | 12/1/2022 | View on chart |
| RCKT | ▲ Buy | Open Market | 1,355,932 | $20.0M | 10/6/2022 | View on chart |
| MIST | ▲ Buy | Open Market | 1,557,346 | $13.6M | 9/7/2022 | View on chart |
| MIST | ▼ Sell | Open Market | 1,557,346 | $13.6M | 9/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
OBIO Shares Rise 5.2% Amid Positive Momentum
Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.
OBIO Shares Rise 5.2% Amid Positive Momentum. Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.